Tweet Douglas Loe, a health care and biotech analyst with Euro Pacific Canada, discussed the state of the sector today in an interview with BNN’s Pamela Richie. Mr. Loe’s buy recommendations include Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) and Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). The interview can be accessed here.
Tweet Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). To ensure a smooth transition of responsibilities, Mr. Andrews will remain with the company for a period of time while the board undertakes a search process. He will then continue working with Cipher in a consulting […]
Tweet Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela is Cipher’s once-daily capsule formulation of tramadol, which has both immediate-release and extended-release components for the treatment of moderate-to-moderately severe chronic pain in adults. “This agreement, […]
Tweet Cipher Pharmaceuticals (TSX:DND) has received Health Canada approval for its CIP-Tramadol ER, an extended-release treatment of moderate to moderately severe chronic pain in adults. “This represents the second regulatory approval for our extended-release tramadol and another important milestone for the company,” CEO Larry Andrews said in a statement. “We believe our product’s unique attributes, […]
Tweet Cipher Pharmaceuticals (TSX:DND) has completed patient enrolment in a Phase 3 safety study of its CIP-Isotretinoin treatment of severe, nodular acne. A total of 931 patients were enrolled in the trial, of which 626 have completed treatment to date. Following an estimated six-month treatment period, the last subject enrolled should complete treatment in April, […]
Tweet The U.S. Patent and Trademark Office has issued a patent notice of allowance for Cipher Pharmaceuticals’ (TSX:DND) CIP-Tramadol ER, an extended-release product for the treatment of moderate to moderately severe chronic pain in adults. Cipher said that after the patent is formally issued, it will pursue an FDA Orange Book listing associated with its […]